(1) Mengwei Li#,  Guangxiang Liu#, Hanmei Xu*, et al. Micropeptide MIAC inhibits the  tumor progression by interacting with AQP2 and inhibiting EREG/EGFR  signaling in renal cell carcinoma. Mol Cancer. 2022, 21(1): 181. (IF 37.3)

(2) Mengwei Li#, Chi, Xiaowei, Xu, Hanmei*, et  al. Trends in insulin resistance: insights into mechanisms and  therapeutic strategy. Signal Transduction and Targeted Therapy. 2022, 7:  1-25. (IF 39.3)

(3) Setrerrahmane S^#, Mengwei Li^#,  Hanmei Xu*, et al. Cancer-related micropeptides encoded by ncRNAs:  Promising drug targets and prognostic biomarkers. Cancer Lett. 2022:  215723. (IF 9.7)

(4) Ying Wang^#, Mengwei Li^#,  Lin Chen, Hanmei Xu*, et al. Natural killer cell-derived exosomal  miR-1249-3p attenuates insulin resistance and inflammation in mouse  models of type 2 diabetes. Signal Transduction and Targeted Therapy.  2021, 6: 1-13. (IF 38.1)

(5) Meng Li^#, Ying Wang^#, Mengwei Li^#, Hanmei Xu*, et al. Integrins as attractive targets for cancer therapeutics. Acta Pharmaceutica Sinica B. 2021, 11: 2726-2737. (IF 14.9)

(6) Mengwei Li^#; Xin Li^#;  Yinan Zhang; Hanmei Xu*, et al. Micropeptide MIAC Inhibits HNSCC  Progression by Interacting with Aquaporin 2. Journal of the American  Chemical Society. 2020, 142: 6708-6716. (IF 15.4)

(7) Mengwei Li^#, Xu Ding^#,  Yinan Zhang, Hanmei Xu*, et al. Antisense oligonucleotides targeting  lncRNA AC104041.1 induces antitumor activity through Wnt2B/β-catenin  pathway in head and neck squamous cell carcinomas. Cell Death &  Disease. 2020, 11: 1-12. (IF 8.5)